MyTomorrows partners with pancreatic cancer pressure group to drive trials [Yahoo! Finance]
RenovoRx, Inc. (RNXT)
Company Research
Source: Yahoo! Finance
novel treatments across the continent by way of the company's clinical trials database. The new partnership will see Pancreatic Cancer Europe utilising the company's database of ongoing clinical trials to equip patients, caregivers, and healthcare professionals with up-to-date information about pre-approval treatments that may be relevant to them. Research published by the European Commission found that in 2020 pancreatic cancer accounted for 3.5% of all new cancer diagnoses and 7.1% of all deaths due to cancer, making it the seventh most frequently occurring cancer, and the fourth leading cause of cancer death after lung. MyTomorrows says that it aims for the partnership to ease the process of identifying and understanding the existing clinical trial options a patient may have, through a new clinical trial search tool. Michel van Harten, CEO of MyTomorrows, said: “We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to rais
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology PhysiciansGlobeNewswire
- RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic CancerGlobeNewswire
- RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.MarketBeat
- RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York [Yahoo! Finance]Yahoo! Finance
RNXT
Earnings
- 11/13/23 - Beat
RNXT
Analyst Actions
- 9/12/24 - Ascendiant Capital
RNXT
Sec Filings
- 10/2/24 - Form 4
- 10/2/24 - Form 4
- 10/2/24 - Form 4
- RNXT's page on the SEC website